Showing 2491-2500 of 9111 results for "".
Noah Worcester 2024: Dr. Greenberg on the Society
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-greenberg-society/24588/Michael Greenberg, MD, president of the Noah Worcester Dermatological Society, speaks at the organization’s 2024 meeting about what makes the event special.Cutaneous Oncology in 2024
https://practicaldermatology.com/conferences/maui-derm-2024/cutaneous-oncology-in-2024/20266/Resident Of Distinction Award-winner Banu Farabi, MD, a PGY-3 resident at New York Medical College, talks about a review she attended highlighting the latest therapeutic approaches to treating conditions such as actinic keratosis and several different types of skin cancer, as well as an overview ofSkin Cancer Prevention: Can Laser Therapy Help?
https://practicaldermatology.com/conferences/scale-2023/skin-cancer-prevention-can-laser-therapy-help/20205/Non-ablative fractional laser treatments may dramatically the reduce risk of skin cancer recurrence. Joel L. Cohen, MD, and Mathew M. Avram, MD, JD, discuss the science behind this intriguing finding.Red Light vs Blue Light Therapy
https://practicaldermatology.com/series/pdt-in-practice/red-light-vs-blue-light-therapy/26993/Dr. Hamza D. Bhatti, a board-certified dermatologist and dually accredited fellowship-trained Mohs micrographic surgeon and cosmetic dermatologic surgeon, discusses the differences between red light and blue light photodynamic therapy (PDT), the advantages of each, and some off-label uses of PDT.Exosomes 101
https://practicaldermatology.com/conferences/scale-2023/exosomes-101/20192/Exosomes are today's hottest skincare ingredient, and Glynis Ablon, MD, gives viewers the scoop on how and when to use them.Skin Cancer Perceptions, Cimzia for Psoriasis, Eczema and CV Risk
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-skin-cancer-perceptions-cimzia-for-psoriasis-eczema-and-cv-risk/18301/A new national survey, Skin Cancer In America 2018, conducted by Health Union, explores perceptions of patients with skin cancer. Cimzia (certolizumab pegol, UCB) has received FDA approval for treatment of adults with moderate to severe plaque psoriasis. Cimzia is the first Fc-free, PEGylated anti TConnective Tissue Disorders Update 2025: Dr. Vleugels
https://reachmd.com/programs/practical-dermatology/connective-tissue-disorders-update-2025-dr-vleugels/32673/Ruth Ann Vleugels, MD, PhD, recaps her presentation, "Connective Tissue Disorders Update 2025" at Maui Derm 2025. Dr. Vleugels discussed a new therapeutic for systemic lupus, a new FDA-approved option for dermatomyositis, JAK inhibitors, and more.A Case Presentation of Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37154/Alina Bridges, DO, Director of Dermatopathology & Associate Professor in the Department of Dermatology and Anatomic Pathology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, presents a case study involving a patient who had been on multiple treatments to present prurituThe Impact of Clascoterone Topical Cream, 1%
https://practicaldermatology.com/issues/april-2025/the-impact-of-clascoterone-topical-cream-1/35605/Clascoterone topical cream, 1% (Winlevi, Sun Pharmaceuticals, Inc.) approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older.Elucidating the Inflammatory Cascade May Help to Turn Out the Lights in Psoriasis
https://practicaldermatology.com/topics/psoriasis/elucidating-the-inflammatory-cascade-may-help-to-turn-out-the-lights-in-psoriasis/19943/Understanding the science behind psoriasis pathogenesis has raised the bar in the management of disease. Watch the video to visualize the patient journey, their unmet needs, and aim to set higher standards in the psoriasis landscape.